- Home
- SDA vs BNR Comparison
SDA vs BNR Comparison
Compare SDA & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SDA | BNR |
|---|---|---|
| Founded | 2007 | 2014 |
| Country | China | China |
| Employees | N/A | N/A |
| Industry | Blank Checks | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 213.2M | 216.9M |
| IPO Year | N/A | 2020 |
Fundamental Metrics
Financial Performance| Metric | SDA | BNR |
|---|---|---|
| Price | $2.05 | $29.23 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.75 | N/A |
| AVG Volume (30 Days) | 47.2K | ★ 47.5K |
| Earning Date | 12-18-2025 | 11-20-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $467,272,000.00 | $75,749,382.00 |
| Revenue This Year | $10.86 | $136.32 |
| Revenue Next Year | $13.07 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 9.69 | 5.56 |
| 52 Week Low | $1.54 | $2.18 |
| 52 Week High | $10.61 | $24.92 |
Technical Indicators
Market Signals| Indicator | SDA | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 53.08 | 69.17 |
| Support Level | $2.02 | $19.10 |
| Resistance Level | $2.15 | $24.92 |
| Average True Range (ATR) | 0.09 | 2.28 |
| MACD | 0.00 | 0.42 |
| Stochastic Oscillator | 57.14 | 89.61 |
Price Performance
Historical ComparisonAbout SDA SunCar Technology Group Inc.
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform.
About BNR Burning Rock Biotech Limited
Burning Rock Biotech Ltd is a cancer diagnostics company. It is a NGS-based cancer therapy selection company. Its cancer therapy selection platform is built upon advanced proprietary technologies, comprehensive portfolio of products and a two-pronged market-driven commercial infrastructure addressing both larger hospitals through company's in-hospital model and smaller hospitals through its central laboratory model. It had three operating segments, including Central laboratory business, In-hospital business and Pharma research and development services. It generates the majority of its revenue from Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, brPROPHET, OncoScreen Plus, and others.